share_log

Walgreens Boots Alliance | 8-K: Current report

Walgreens Boots Alliance | 8-K: Current report

沃爾格林-聯合博姿 | 8-K：重大事件
美股sec公告 ·  05/01 17:03
Moomoo AI 已提取核心訊息
Walgreens Boots Alliance, Inc. (Walgreens) has reached a settlement in a shareholder derivative suit involving allegations of inadequate oversight of opioid-related matters. The suit, initially filed in Ohio and later refiled in Illinois, claimed that certain officers and directors breached fiduciary duties by failing to ensure compliance with the Controlled Substances Act, exposing the company to liability. The settlement, mediated by Hon. Layn R. Phillips (Ret.), includes a $36 million payment from directors and officers insurance carriers and the implementation of corporate governance reforms for at least five years. The reforms include the creation of a Compliance, Safety, and Quality Committee, the appointment of two new independent directors, and the establishment of a U.S. Retail Pharmacy Governance, Risk, and Compliance Committee, among other changes. The settlement is subject to court approval, with a hearing scheduled to determine its fairness, reasonableness, and adequacy, as well as to address any objections from shareholders.
Walgreens Boots Alliance, Inc. (Walgreens) has reached a settlement in a shareholder derivative suit involving allegations of inadequate oversight of opioid-related matters. The suit, initially filed in Ohio and later refiled in Illinois, claimed that certain officers and directors breached fiduciary duties by failing to ensure compliance with the Controlled Substances Act, exposing the company to liability. The settlement, mediated by Hon. Layn R. Phillips (Ret.), includes a $36 million payment from directors and officers insurance carriers and the implementation of corporate governance reforms for at least five years. The reforms include the creation of a Compliance, Safety, and Quality Committee, the appointment of two new independent directors, and the establishment of a U.S. Retail Pharmacy Governance, Risk, and Compliance Committee, among other changes. The settlement is subject to court approval, with a hearing scheduled to determine its fairness, reasonableness, and adequacy, as well as to address any objections from shareholders.
Walgreens Boots Alliance, Inc.（Walgreens）已就一項股東衍生訴訟達成和解，該訴訟涉及對阿片類藥物相關事項監督不力的指控。該訴訟最初在俄亥俄州提起，後來在伊利諾伊州重新提起，聲稱某些高管和董事未能確保遵守《管制物質法》，從而違反了信託義務，使公司面臨責任。該和解協議由萊恩·菲利普斯閣下（退休）調解，包括董事和高級管理人員保險公司支付的3,600萬美元款項，以及實施至少五年的公司治理改革。這些改革包括成立合規、安全和質量委員會，任命兩名新的獨立董事，以及成立美國零售藥房治理、風險和合規委員會等。該和解尚待法院批准，並計劃舉行聽證會，以確定其公平性、合理性和充分性，並解決股東的任何異議。
Walgreens Boots Alliance, Inc.（Walgreens）已就一項股東衍生訴訟達成和解，該訴訟涉及對阿片類藥物相關事項監督不力的指控。該訴訟最初在俄亥俄州提起，後來在伊利諾伊州重新提起，聲稱某些高管和董事未能確保遵守《管制物質法》，從而違反了信託義務，使公司面臨責任。該和解協議由萊恩·菲利普斯閣下（退休）調解，包括董事和高級管理人員保險公司支付的3,600萬美元款項，以及實施至少五年的公司治理改革。這些改革包括成立合規、安全和質量委員會，任命兩名新的獨立董事，以及成立美國零售藥房治理、風險和合規委員會等。該和解尚待法院批准，並計劃舉行聽證會，以確定其公平性、合理性和充分性，並解決股東的任何異議。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息